StockData
Pfizer Inc logo

Pfizer Inc

PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3053% above fair value
$30.52+0.57 (+1.90%)

Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%

Pfizer Padcev (enfortumab vedotin ADC by Year

Padcev (enfortumab vedotin ADC — urothelial cancer, via Seagen) — Worldwide reported YoY (%) (%)

QuarterlyAnnual

Pfizer Padcev (enfortumab vedotin ADC: 22.0% in FY2025.

Latest, FY2025
22.0%
Period ended Dec 31, 2025
Change on a year earlier
–
History
1 years
Since FY2025
Sources
1
Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03)

Where the FY2025 figure comes from

“|| Padcev | 1,940 | 1,588 | 22% | 22% | 1,902 | 1,561 | 22% | 38 | 27 | 42% | 43%”

Source: Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗

Reported in Form 8-K Revenue Tables.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedPadcev (enfortumab vedotin ADC — urothelial cancer, via Seagen) — Worldwide reported YoY (%) (%)Year on yearSource
FY2025Dec 31, 202522.0%–Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗

Cite this data

StockData. (2026). Pfizer Padcev (enfortumab vedotin ADC (%), annual FY2025–FY2025 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/padcev-yoy-ww

See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.